Elixxer Valuation
| ELXR Stock | CAD 1.15 0.00 0.00% |
Today, the firm appears to be fairly valued. Elixxer shows a prevailing Real Value of C$1.15 per share. The current price of the firm is C$1.15. Our model computes the value of Elixxer from reviewing the firm fundamentals such as Shares Owned By Institutions of 32.04 %, price to sales of 767,774 X, and Current Valuation of 21.92 M as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 2.669 | Enterprise Value 21.9 M | Enterprise Value Ebitda (2.63) | Price Sales 767.8 K | Enterprise Value Revenue 113.5261 |
Fairly Valued
Today
Please note that Elixxer's price fluctuation is very steady at this time. Calculation of the real value of Elixxer is based on 3 months time horizon. Increasing Elixxer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Elixxer stock is determined by what a typical buyer is willing to pay for full or partial control of Elixxer. Since Elixxer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Elixxer Stock. However, Elixxer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.15 | Real 1.15 | Hype 1.15 | Naive 1.15 |
The intrinsic value of Elixxer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Elixxer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Elixxer helps investors to forecast how Elixxer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Elixxer more accurately as focusing exclusively on Elixxer's fundamentals will not take into account other important factors: Elixxer Cash |
|
Elixxer Total Value Analysis
Elixxer is currently anticipated to have takeover price of 21.92 M with market capitalization of 13.05 M, debt of 11.91 M, and cash on hands of 969.92 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Elixxer fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.92 M | 13.05 M | 11.91 M | 969.92 K |
Elixxer Asset Utilization
One of the ways to look at asset utilization of Elixxer is to check how much profit was generated for every dollar of assets it reports. Elixxer shows a negative utilization of assets of -0.3 percent, losing C$0.003042 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Elixxer shows how discouraging it operates for each dollar spent on its assets.Elixxer Ownership Allocation
The market capitalization of Elixxer is C$13.05 Million. 30% of Elixxer outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Elixxer Profitability Analysis
Net Loss for the year was (3.47 M) with profit before overhead, payroll, taxes, and interest of 42.41 K.About Elixxer Valuation
Our relative valuation model uses a comparative analysis of Elixxer. We calculate exposure to Elixxer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Elixxer's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -9 M | -8.6 M |
Additional Tools for Elixxer Stock Analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.